Randox showcases brand new innovations at world’s largest diagnostics conference
Global diagnostics firm Randox will next month showcase its unique life science capabilities in areas including Stroke differentiation and quality control for a range of infectious diseases, at the world’s largest laboratory medicine conference – the AACC Annual Scientific Meeting & Clinical Lab Expo – in California.
The 71st event from the American Association for Clinical Chemistry (AACC) is set to highlight the best in the industry on the world stage once again as clinicians, companies and customers from all over the world flock to the Californian Anaheim Convention Centre from Sunday 4th to Thursday 8th August 2019.
“We look forward to AACC every year as we exhibit our constantly-evolving revolutionary technologies,” said Randox Managing Director, Dr. Peter FitzGerald.
“This year we will once again highlight Randox’s ground-breaking diagnostic products and services which help to save and extend lives across the world.”
Launching at this year’s AACC event are a number of exciting new innovations from Randox, including a new offering of Infectious Disease Serology Internal Quality Controls which includes quality control material vital for the testing of HIV, Hepatitis A, Congenital infections and even Lyme Disease.
Dr. FitzGerald continued;
“We are delighted to bring our Infectious Disease Serology Internal Quality Control portfolio to market for the first time. There are approximately 1 million people in the US living with HIV and around 15% unaware they are infected.
“The impact of all infectious diseases, including HIV, is increasing and, therefore, laboratories play an increasingly larger role in providing accurate results. This is a key component in controlling the spread of infection.”
At AACC Randox will also be unveiling its brand new Randox Stroke Biochip, an advancement of its Biochip Array Technology in which an investment of £305 million has been invested to date. This disruptive technology is set to enhance CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.
Dr FitzGerald added;
“We are pleased to highlight our brand new Randox Stroke Biochip which is set to revolutionise stroke differentiation when time is of the essence. There is great tragedy in the fact that the majority of stroke damage can be minimised if intervention is delivered on time.
“Our stroke test is the vital next step – assisting clinicians in making a rapid diagnosis and differentiation between haemorrhagic and ischaemic stroke, so their patients get the right treatment at the right time.”
Randox look forward to showcasing the latest innovations in diagnostic capabilities at AACC 2019 as they strive to attain earlier diagnoses and, subsequently, earlier treatment and intervention which will directly impact on positive outcomes and reduce the burden on healthcare services. From Stroke and HIV to Lyme Disease and Hepatitis A virus, the company’s innovative technologies facilitate improved prognosis for patients when it matters most.
AACC runs from the 4th to the 8th of August 2019 at Anaheim Convention Centre, Anaheim, California. Randox can be found at booth #1101.
Leading diagnostics firm Randox Laboratories has this week sent a delegation of scientists from its Biosciences Division to take part in the UK Exhibition of Oncology Excellence, between 25th and 29th June in Beijing and Guangzhou, in China.
The centrepiece of the UK-China Oncology Congress, the exhibition has been carefully curated to follow the “Science to Patient Pathway” for new therapies – from research to clinical trials, regulatory approval, manufacturing and distribution.
The Randox Biosciences team, over the course of the Congress event, will join a range of cancer-related seminars, offering an opportunity to learn about and influence Chinese government policies and priorities, and explore the latest trends and hot topics in oncology.
Julie-Ann O’Hare, Sales and Marketing Director for Randox Biosciences, commented;
“At Randox Biosciences we are actively seeking opportunities to strengthen business ties between the UK and China, and of course to showcase our innovative diagnostic capabilities to what is one of our most important and growing markets.
“We continue to expand our business presence there thanks to the ongoing pipeline of novel tests being produced from our innovative research and development programmes and enhanced manufacturing capabilities, including new facilities at the Randox Science Park in Northern Ireland.”
Exhibiting to a diverse audience of universities, hospitals, and laboratories responsible for prevention, diagnosis, treatment and care in oncology, Randox Biosciences have joined the exhibition to showcase their innovative diagnostic tests for bladder cancer and early detection of renal toxicity – including Chronic Kidney Disease and Acute Kidney Injury.
“We continue to offer an increasing range of innovative diagnostic biomarkers to the growing and dynamic biotechnology markets.
“The focus on the importance of scientific research in the patient pathway, in enabling cancer diagnoses as soon as possible, offers us the perfect platform to introduce to China our latest pioneering oncological tests, including our test for bladder cancer.
“This test can stratify patients with haemeaturia (blood in the urine), who are at high risk of bladder cancer – reducing the number of unnecessary cystoscopies carried out on patients identified as ‘low risk’, significantly reducing healthcare costs and improving the waiting times for haematuria patients.”
For further information about the UK-China Oncology Congress, please email email@example.com
A partnership between Randox Laboratories, the UK’s largest manufacturer of in-vitro diagnostics, and the German technology giant Bosch is changing the way doctors will treat patients with antibiotics, with the launch of a revolutionary product – the Vivalytic.
It’s estimated that 20% of antibiotics currently prescribed are unnecessary, and fuel the growing threat of global antibiotic resistance. This threatens the ability to treat common infectious diseases, and a growing number are becoming harder, and in some cases impossible, to treat. The World Health Organisation warns that without action, we are heading towards a post-antibiotic era.
This problem is being addressed by the Vivalytic. The result of a decade of R&D, it is an intuitive point-of-care analyser that, depending on the complexity of the test, will deliver results from 30 minutes: enabling doctors to select the right course of therapy faster than before. In some cases, this will be life-saving.
The first tests available on the Vivalytic are Randox’s panels for respiratory and sexually-transmitted infections*.
Using Randox’s patented Biochip Array Technology, the Respiratory Multiplex Array simultaneously reports on 22 viral and bacterial pathogens including Bordetella pertussis and parapertussis which causes whooping cough – without the need for secondary or confirmatory testing to inform clinical treatment decisions. The STI array enables the detection of 10 STIs from a single sample. Every day more than 1 million STIs are acquired, and many have mild if any symptoms at all. Identifying these infections correctly first time reduces the misuse of antibiotics and supports their targeted use.
The Managing Director of Randox Dr Peter FitzGerald commented:
“Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. This partnership is ideal, combining our expertise in molecular laboratory diagnostics with Bosch’s cutting-edge engineering. The Vivalytic is a game-changer for clinicians and patients: never before has there been this level of accessibility to this range of molecular diagnostics.”
Marc Meier, General Manager of Bosch Healthcare Solutions, a wholly owned subsidiary of Bosch Group, said:
“We are enthusiastic about having gained Randox as the first partner on our platform with two initial panels available from the start. It´s the beginning of jointly expanding the Vivalytic test portfolio for our clients. In this partnership the core competencies of Bosch in automation, miniaturization, and networking are complemented by Randox’s expertise in developing and commercializing innovative diagnostic solutions.”
Vivalytic and the panels will be presented to industry professionals for the first time at the ECCMID 2018 Congress in Madrid, Spain, in hall 10, booth 55A between 21st – 24th April.
*CE pending and FDA planned.
For further information about the Vivalytic, please contact firstname.lastname@example.org
Randox Laboratories, the world-leading medical diagnostics manufacturer, is showcasing advancements in laboratory technology at the 2017 MEDICA – World Conference for Medicine conference, being held November 13-16 in Dusseldorf, Germany.
Unveiling its state-of-the-art interactive exhibition stand, Randox will host a series of demonstrations of its innovative analysers including the Evidence Evolution and Rx modena, and a number of exciting advances in laboratory medicine, involving increasing the test menu available to clinicians and improving the connectivity of laboratories across the world to improve overall quality.
“Through our advancements in laboratory innovation, we’re driving an industry-wide evolution” said Randox CEO, Dr Peter FitzGerald.
“Our products are leading the way in innovation and enabling laboratories to transform the way they operate. We will be hosting demonstrations of a wide range of our fully-automated analysers, which are packed with cutting-edge technology and intuitive software. The goal is to provide future-proof diagnostic technology that will create the most efficient and effective laboratories.”
Paving the way is Randox’s patented Biochip Array Technology (BAT). This multi-analyte testing platform is the product of a £250 million research and development project. The ceramic tile measuring 9×9 mm can currently run up to 49 assays simultaneously,100 assays in the near future. This innovation allows the simultaneous quantitative or qualitative detection from a wide range of analytes from a single sample. It is suitable for use in a wide range of laboratories including clinical, research, hospital, veterinary and forensic and clinical toxicology.
To enhance the benefits of BAT, Randox introduced the Evidence Evolution to its stable of immunoassay analyser platforms. The Evidence Evolution is the world’s first fully automated random-access biochip testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.
Joining the Evolution in Hall 3 stand A08 is the RX modena. This highly reliable, precise, fully automated clinical chemistry analyser can run 1200 tests per hour including ISE. When combined with its unrivalled RX series test menu, it offers a winning combination for all large, multi-disciplinary laboratories.
“We develop more new tests than any other diagnostics manufacturer, and one of the products that we’re showcasing at this year’s MEDICA is Adiponectin,” added Susan Hammond, Global Sales Manager at Randox.
“This novel biomarker is a powerful new weapon in the fight against some of the biggest health issues faced throughout the world including diabetes, cancers and cardiovascular disease. As it’s World Diabetes Day on Tuesday 14th November, it’s a great opportunity to draw attention to this array which labs can run as part of their routine testing panel.”
MEDICA attendees will also be among the first to experience the advancements delivered by the latest update for Randox’s Acusera 24.7. This online interlaboratory data management and peer reporting package is now smarter, faster and more powerful than ever before.
Acusera 24.7 is designed to help laboratories efficiently review QC data from all their lab instruments on one central platform, thereby allowing quick and easy identification of QC failures and emerging trends. Unique access to peer group data updated instantly in real-time from our global network of laboratory participants will speed up troubleshooting and help pinpoint the root cause of any QC failures by easily identifying if an issue is isolated or widespread.
The Randox team will be on hand throughout MEDICA 2017 at stand #3A08. To make an appointment in advance, contact them through the Randox MEDICA webpage.
Diagnostic engineering company, Randox Teoranta, has been officially announced as the main sponsor of the Engineering Technology Teachers’ Association (ETTA) conference. Randox Teoranta, based in Donegal’s coastal town Dungloe, is the global diagnostic company’s hub for world-leading engineering and life sciences in the west of Ireland.
Randox Teoranta’s sponsorship of the renowned ETTA awards comes as it aims to attract Ireland’s top engineers and scientists to join the team which is based in its next-generation life science, engineering, research and manufacturing centre in Donegal.
The company is recognised globally for its commitment to improving healthcare and technology, and in the past year alone scientists and engineers at Randox Teoranta have developed a revolutionary test for Alzheimer’s disease, designed drug testing software to be used by police officers in criminal investigations, and engineered new technologies with the ability to detect disease and save lives. The team is currently working on cutting-edge research for key health issues including kidney disease, thyroid disease and gastrointestinal disorders.
ETTA is a voluntarily administered association which represents teachers of Engineering Technology and Metalwork. Its focus is to promote technology as an exciting career choice for young people, providing a National Engineering Awards programme for second level students. It works in conjunction with Engineers Ireland, third level colleges and the Department of Education to ensure the highest standards of Engineering Technology education.
In attendance on the launch evening in the Letterkenny Institute of Technology were Christina Mc Fadden, Breid Gallagher and Daniel Melly representing Randox Teoranta; Denis Mc Fadden and Jim Morrison from LYIT; and Dr. Martin Gormley, Director of Schools in Donegal ETB. There was also an excellent turnout from branch members on the night.
Chairperson of the Donegal Branch of the ETTA, Sean Mc Fadden said,
“We would like to acknowledge Randox Teoranta and express our sincere thanks on becoming the main sponsors for the ETTA National Conference 2017, bringing their wealth of knowledge, resources and expertise in the field of engineering to the table. Randox has been bringing high-end engineering employment to Donegal since it opened and are always enthusiastic to develop links with the Education sector here. The expansion of Randox Teoranta is an exciting prospect for many of our students with world-class engineering and technology now right on their doorstep.”
Christina Mc Fadden, Engineering Manager at Randox Teoranta said:
“We’re delighted to support these awards which honour the very best engineering students in Ireland. Randox’s success owes a great deal to our team of engineers who hold a prestigious MacRobert Award and are constantly driving new innovations that transform patients’ lives around the world. Since opening our R&D and manufacturing centre in Dungloe in 2010, we’ve provided unrivalled opportunities to mechanical, software and electrical engineers. We are committed to encouraging more people to see engineering as a viable career option, and then to ensure our very talented students are able to pursue outstanding careers here on this island.”
The ETTA Conference and Awards Ceremony will be hosted by Letterkenny Institute of Technology (LYIT) on Friday 17th and Saturday 18th November 2017.
For further information about the Randox Teoranta sponsorship of the ETTA Awards, please contact Randox PR by phoning 028 9445 1016 or emailing RandoxPR@randox.com
A group of 30 delegates from global healthcare company Randox Laboratories has this week travelled to the USA, to take part in the world’s largest diagnostics conference – in San Diego, California.
The American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, known as the leading event for laboratory medicine worldwide, is attended by over 20,000 delegates from across the globe, and offers Randox the opportunity to showcase their capabilities and to network with leading healthcare professionals and key decision makers.
Launching at this year’s event are a number of innovative and exciting new products, including a test for Acute Kidney Injury, a revolutionary diagnostic for small, dense low density lipoprotein (sLDL), a subtype of LDL cholesterol which is a vital risk marker for cardiovascular disease, and the latest in laboratory quality assurance software.
Chief Scientist at Randox Laboratories, John Lamont, who is heading up the delegation to the US, commented;
“Our very significant investment in research and development means that we have more new tests in development than any other healthcare company in the world. Each year at AACC we are able to bring a wealth of exciting new technologies to the American market, for a range of the world’s pressing health issues in need of the most urgent address. We look forward to showcasing our latest innovations at this year’s AACC conference, and to identifying further potential projects.”
Dr. Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;
“We appreciate that post-Brexit there will of course be particular business challenges with regards to international business, but at Randox we will remain committed to developing new health diagnostic technologies in the areas where they are needed most, and to expanding the business in our key markets, such as the US.
“The USA is one of our most important markets and we have been exporting our diagnostic products there since the early 1980s. We will continue to nurture our presence there, the expansion of which will be supported by our soon to be opened facility in Kearneysville, West Virginia, which will enable us to strengthen our position in that market.”
AACC runs from the 30th July – 3rd August at the San Diego Convention Centre. Randox can be found at booth #3839.
For further information about Randox at AACC please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
Following the launch of its new Chinese market expansion programme in December 2016, global healthcare diagnostics company Randox Laboratories has made significant strides in its business with China, successfully increasing its exports and enabling new business opportunities within the country.
The firm has just returned from a business trip to China to meet new distributors and customers acquired over the last six months, and to train this recently acquired distributor network on Randox’s latest healthcare technologies, with a key focus on the company’s RIQAS programme, the world’s largest External Quality Assessment scheme for laboratories.
Ying Zhu, Sales Manager for Randox Laboratories in China, commented on the success Randox has seen in China over the last six months;
“China is one of our key markets and although our world-leading diagnostic products have been sold there for more than 20 years, we continue to increase our business presence there thanks to increased output from our innovative R&D programmes, and enhanced manufacturing capabilities, including new facilities at the Randox Science Park, our new headquarters in County Antrim. These infrastructural developments have resulted in an increasing range of products which we can now offer to growing and dynamic markets such as China. This increasing range of products coupled with a growing market presence has significantly increased our business penetration and subsequent support to customers.”
Since the launch of the market expansion programme last year Randox has successfully secured distributors across four of the largest provinces of China and has partnered with key hospitals in Guangzhou, Shanghai and Wuhan.
Margaret Fick, RIQAS Scientist added;
“At our most recent training conference in China, in addition to the educational seminars I conducted with my colleagues, we were also delighted to be able to host several of our newly acquired hospital partners, who presented to our audience of current and potential customers on how their laboratories have benefited from our Randox Quality Control products. The use of testimonials from high profile individuals who have experienced the quality, efficiency and reliability of our products is accelerating our growth across China and this is set to continue over the coming months and years.”
For further information about Randox in China please contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
Global healthcare company Randox, which is headquartered in Co Antrim and has key R&D, engineering and manufacturing facilities in both Co Antrim and Co Donegal, has been named in The US-Ireland Top 50 Companies, to be announced today, Friday 16th June, at the New York/New Belfast conference in Manhattan.
With a focus on the transatlantic operations building bridges between the two countries, the awards celebrate those bringing business in Ireland to global heights in the belief that by doing so they are embedding peace for future generations.
The 50 honourees will be announced at a gala event hosted by the Irish Echo, the USA’s largest and most widely read Irish American weekly paper, at Pier A, Harbor House.
The tenth annual celebration will be addressed by Constance Hunter, Chief Economist of KPMG and Daniel Dromm, NYC City Council member and Chair of the Education Committee, and takes place as part of the two-day conference. This prestigious event highlights the progress and prosperity of both cities, and looks optimistically to the future while celebrating our shared past.
Movie makers, scientists, tech companies and engineers have been among those who have received the plaudit in recent years. They have included the all-conquering production company, HBO; leading law firm A&L Goodbody; pioneers in scientific imaging Andor Technology and the New York Stock Exchange.
This year’s US-Ireland Top 50 has proven to be just as illustrious with Randox Laboratories, Northern Property, Norwegian Airlines, and Bank of Ireland as just some of the companies being recognised for their success.
Editor of the Irish Echo, Ray O’Hanlon, who will host Friday’s event, said the awards were an acknowledgment of the unique bonds between the two nations.
“The unmistakable and unbreakable bonds between Ireland and the United States have proven a key element in Ireland’s progression, both in terms of peace and prosperity. Those bonds grow ever stronger when underpinned by economic growth and business relationships. With the Ireland-US Top 50 we acknowledge those companies whose transatlantic operations support that ongoing development and welcome them to this illustrious list of business beacons.”
Dr. Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;
“The US is one of our most important markets and we have been exporting our diagnostic products there since the early 1980s. We have seen substantial success in this market and have secured for example, key clinical chemistry analyser contracts in Ivy League Institutions such as Yale University School of Medicine and Harvard University.
“Our diversification into the veterinary, research, forensic and food safety sectors has enabled our operations in the US to expand further still, and due to this increasing demand for Randox innovations, we are developing a new facility in the Greater Washington DC area.
“It is a tribute to the entire Randox team, both in Co Antrim and Co Donegal, that we have been named as one of the US-Ireland Top 50. We hope to serve as an example to other aspiring businesses that success is possible with a unique product offering, a commitment to investment, and making use of the support network available across the United States.”
For further information about the New York New Belfast Conference contact Randox PR on 028 9445 1016 or email RandoxPR@randox.com
Global healthcare firm Randox Laboratories has pledged its commitment to maintaining and developing its business relationships with Europe, as a group of 20 representatives from the diagnostics company have travelled to Greece this week, to take part in one of Europe’s largest diagnostics conference in Athens.
EuroMedLab, which is run by the European Congress of Clinical Chemistry and Laboratory Medicine, is attended by thousands of healthcare professionals from across the globe, and offers Randox the opportunity to showcase their capabilities and to network with key decision makers.
Managing Director of Randox, Dr. Peter FitzGerald, commented on what the company hopes to achieve by attending EuroMedLab;
“We highly value the business we do within the European market and have successfully made a name for ourselves in the diagnostics industry in these countries. We already have a number of key sales offices and distribution centres in the likes of France, Germany, Portugal, Italy, Spain and Poland, but there is so much more we can do. Attending key networking events such as EuroMedLab is vital because it allows us the opportunity to meet with our existing customers and partners, to nurture and develop these relationships, and of course establish new ones.”
At the EuroMedLab conference the delegation team of Randox scientists, business development executives and market researchers will be making a series of announcements and presentations for new products including an innovative stroke diagnostic, newly discovered biomarkers for coronary heart disease risk, and the latest in laboratory quality assurance software.
The team will also present for the first time the Evidence Evolution analyser, a biochip testing platform capable of delivering accurate results from more than 2600 tests an hour including, but not exclusive to, cancer surveillance, fertility, heart, nutritional, digestive and diabetes health.
Dr. FitzGerald continued;
“At Randox we invest up to 16% of our turnover in R&D and we therefore have more new tests in development than any other diagnostics company in the world. This puts us in a very unique position in the market because our new developments, which are focused in areas where they are needed the most, successfully address the most urgent health issues.
“In light of recent political developments, there will of course be particular business challenges in Europe, but at Randox we will maintain our commitment to nurturing our relationships with key business partners in Europe and to seeking new opportunities in international markets such as the US.”
EuroMedLab runs from the 11th – 15th June 2017 at the Megaron Athens International Conference Centre in Athens. Randox can be found at booth #13 in the Skalkotas Hall Foyer.